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Multiple sclerosis (MS) is a neurodegenerative disease caused by demyelination in the central nervous
system. In previous studies, serum uric acid (UA) levels have been implied as a useful biomarker in
understanding MS disease progression and development. The majority of previous studies have found
MS patients have a lower UA level than healthy controls, however some studies have found higher UA
levels with MS patients. Previous studies have compared UA levels between subtypes of MS, but have
not produced conclusive data. To better understand the correlation between UA levels and MS
patients, we compared UA levels between our set of MS patients from the Vanderbilt BioVU database,
which includes the electronic health records of ~7,000 MS patients.

BioVU is a resource of over 180,000 leftover blood samples from outpatients that have been collected
and used to extract DNA, and each sample is linked to the individual’s clinical data through a “synthetic
derivative” of their de-identified EMR.

In 499 MS patients and 276 healthy controls with UA results, Both gender and age were found to be
contributing factors to UA levels (p = 5.979e-10 and p=4.448e-5). With both age and gender as
covariates, we found no significant different UA levels associated with MS patients (regression,
p=0.0858). UA levels were compared to MS subtype with no significant association (p = 0.628)

Most of the MS patients in our study have been seen at the Multiple Sclerosis Clinic by one of three
physicians. The Vanderbilt MS Clinic was established in 1994 and up to 30 patients are seen each day.
In general, patients at the MS Clinic are seen twice a year. Additionally, some patients in our study
were seen at Vanderbilt in other clinics for other reasons but also have a diagnosis of MS.

Our study failed to support previous evidence of low UA levels associated with MS patients. Gender
and age were identified as contributing factors to UA level. There was no significant difference found
between UA levels of different subtypes of MS.

The cohort for this study included all MS patients with UA values (499 individuals) and a set of healthy
controls (276 individuals).
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Patients diagnosed with MS and had uric acid values were extracted from our parent dataset. To
account for multiple testing with individuals, median uric acid values were isolated for each individual.
When median value was an average between two numbers, the date associated with the closest value
was chosen. When values were equivalent, the more recent date was utilized. Our cases and controls
were first analyzed for normality of sampling distribution. The sampling distributions are visualized in
figure 1 after removing one outlier from the cases and one from the controls. The sampling distribution
was assessed to be normal.
Gender was determined to be a contributing factor with males having a significantly higher average UA
level. This was confirmed through a two sample t test comparing the median uric acid values of males
to females in our entire population (p = 1.360e-18) and displayed in figure 2. Through linear regression
analysis, age was also found to be a significant contributing factor to uric acid levels (p = 6.002e-6) and
displayed in figure 3.
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Multiple Sclerosis (MS) is a neurodegenerative disease caused by demyelination in the central nervous
system. In previous studies, serum uric acid (UA) levels have been implied as a useful biomarker in
understanding MS disease progression and development. The majority of previous studies have found
MS patients have a lower UA level than healthy controls, however some studies have found higher UA
levels with MS patients. Previous studies have compared UA levels between subtypes of MS, but have
not produced conclusive data. To better understand the correlation between UA levels and MS
patients, we compared UA levels between our set of MS patients from the Vanderbilt BioVU database,
which includes the electronic health records of ~7,000 MS patients.

Patients in BioVU are representative of all patients that come to VUMC, in that they come from diverse
regions of the country, varied ethnicities and health statuses, and are of all ages. We have limited our
study to patients 18 years or older. EMR usage at Vanderbilt dates back to 1997, so we have over 10
years worth of clinical information for many patients.
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Figure 2

UA levels of cases and controls were compared to each other through regression analysis with age and
gender included as covariates with no significant difference found (p = 0.0858). To determine whether
subtype is a contributing factor in UA level, 45 Relapsing Remitting MS (RRMS) individuals were
compared with 13 Primary Progressive MS (PPMS) in a regression analysis with age and gender as
covariates. No significant difference was found between the two groups (figure 4).

Figure 3
Figure 4

Our study failed to support previously established conclusions relating uric acid levels to MS and to MS subtype. The correlation between low uric acid levels and MS diagnosis is near significance and this may be rectified
through a larger sample. However, similar studies failed to include age and gender as covariates in their comparison of MS to UA levels. This points out a possible flaw that necessitates further investigation. The subtype
analysis was only performed on a small fraction of our population (58 of 499). Acquiring additional subtype data would give our study greater power. Using a more specific measurement of MS progression than subtype
classification would also provide more power to our study.

The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center’s BioVU which is supported by institutional funding, the 1S10RR025141-01 instrumentation award, and by the CTSA
grant UL1TR000445 from NCATS/NIH.

